Dasatinib Combined with Interferon-alfa Induces a Complete Cytogenetic Response and Major Molecular Response in a Patient with Chronic Myelogenous Leukemia Harboring the T315I BCR-ABL1 Mutation-Reference-Cited by-同舟云学术

Dasatinib Combined with Interferon-alfa Induces a Complete Cytogenetic Response and Major Molecular Response in a Patient with Chronic Myelogenous Leukemia Harboring the T315I BCR-ABL1 Mutation

Published:2011-06 Issue: Volume:11 Page:S111-S113
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Cornelison A. Megan,Welch Mary-Alma,Koller Charles,Jabbour Elias

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference19 articles.

1. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate;Jabbour;Leukemia,2006

2. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia;Apperley;Lancet Oncol,2007

3. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia;Quintas-Cardama;Cancer Control,2009

4. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy;Jabbour;Blood,2008

5. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-abl;Weisberg;Cancer Cell,2005

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy;Medicine in Drug Discovery;2024-09

2. Management of chronic myeloid leukemia in 2023 – common ground and common sense;Blood Cancer Journal;2023-04-24

3. Treatment Options in CML Resistant or Intolerant to Second-Generation Tyrosine Kinase Inhibitors;Pathogenesis and Treatment of Leukemia;2023

4. Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel;Critical Reviews in Oncology/Hematology;2017-12

5. Deep molecular response by IFN-α and dasatinib combination in a patient with T315I-mutated chronic myeloid leukemia;Pharmacogenomics;2016-07